Actively Recruiting
Efficacy Biomarkers of DAOIB for Dementia
Led by Chang Gung Memorial Hospital · Updated on 2026-03-19
123
Participants Needed
2
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This open-label clinical trial will enroll patients with aMCI or mild AD, and they will be treated with DAOIB for 24 weeks. We will assess the patients before entering the study, 8 weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood NMDA and oxidative stress - related biomarkers every 8 weeks. We hypothesize that NMDA and oxidative stress - related biomarkers can predict the efficacy of DAOIB for patients with aMCI or mild AD.
CONDITIONS
Official Title
Efficacy Biomarkers of DAOIB for Dementia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
- Mini-Mental State Examination (MMSE) score between 10 and 26
- Clinical Dementia Rating (CDR) of 1 or 0.5
You will not qualify if you...
- Hachinski Ischemic Score greater than 4
- History of substance abuse or dependence
- Diagnosis of Parkinson disease, epilepsy, or dementia with psychotic features
- Diagnosis of major depressive disorder
- Presence of major physical illnesses
- Severe visual or hearing impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan, 886
Actively Recruiting
2
China Medical University Hospital
Taichung, Taiwan
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here